These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37365642)

  • 1. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
    Balke-Want H; Keerthi V; Gkitsas N; Mancini AG; Kurgan GL; Fowler C; Xu P; Liu X; Asano K; Patel S; Fisher CJ; Brown AK; Tunuguntla RH; Patel S; Sotillo E; Mackall CL; Feldman SA
    Mol Cancer; 2023 Jun; 22(1):100. PubMed ID: 37365642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
    Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological interventions enhance virus-free generation of
    Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
    Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy.
    Odé Z; Condori J; Peterson N; Zhou S; Krenciute G
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
    Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
    Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.
    Shy BR; Vykunta VS; Ha A; Talbot A; Roth TL; Nguyen DN; Pfeifer WG; Chen YY; Blaeschke F; Shifrut E; Vedova S; Mamedov MR; Chung JJ; Li H; Yu R; Wu D; Wolf J; Martin TG; Castro CE; Ye L; Esensten JH; Eyquem J; Marson A
    Nat Biotechnol; 2023 Apr; 41(4):521-531. PubMed ID: 36008610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Tripartite Gene Editing Machinery for Highly Efficient Non-Viral Targeted Genome Integration.
    Nam H; Xie K; Majumdar I; Yang S; Starzyk J; Lee D; Shan R; Li J; Wu H
    Res Sq; 2023 Oct; ():. PubMed ID: 37961210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
    Ding R; Chao CC; Gao Q
    Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System.
    Moço PD; Farnós O; Sharon D; Kamen AA
    Curr Issues Mol Biol; 2023 Sep; 45(10):7705-7720. PubMed ID: 37886930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transposase-CRISPR mediated targeted integration (TransCRISTI) in the human genome.
    Rezazade Bazaz M; Ghahramani Seno MM; Dehghani H
    Sci Rep; 2022 Mar; 12(1):3390. PubMed ID: 35232993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic priming of GD2
    Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji QH; Skala MC; Capitini CM; Saha K
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101249. PubMed ID: 38699288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking.
    Kelly JJ; Saee-Marand M; Nyström NN; Evans MM; Chen Y; Martinez FM; Hamilton AM; Ronald JA
    Sci Adv; 2021 Jan; 7(4):. PubMed ID: 33523917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-free CRISPR knock-in of a chimeric antigen receptor into
    Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ssDNA is not superior to dsDNA as long HDR donors for CRISPR-mediated endogenous gene tagging in human diploid RPE1 and HCT116 cells.
    Mabuchi A; Hata S; Genova M; Tei C; Ito KK; Hirota M; Komori T; Fukuyama M; Chinen T; Toyoda A; Kitagawa D
    BMC Genomics; 2023 May; 24(1):289. PubMed ID: 37248464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-Cutting and Integrating CRISPR Plasmids Enable Targeted Genomic Integration of Genetic Payloads for Rapid Cell Engineering.
    Bloemberg D; Sosa-Miranda CD; Nguyen T; Weeratna RD; McComb S
    CRISPR J; 2021 Feb; 4(1):104-119. PubMed ID: 33616439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
    Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-mediated homology-directed repair by ssODNs in zebrafish induces complex mutational patterns resulting from genomic integration of repair-template fragments.
    Boel A; De Saffel H; Steyaert W; Callewaert B; De Paepe A; Coucke PJ; Willaert A
    Dis Model Mech; 2018 Oct; 11(10):. PubMed ID: 30355591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.